Ikena Oncology, Inc. shared initial data from twenty-six (26) patients treated in the ongoing dose escalation portion of the Phase I clinical trial of IK-930, a novel, oral, potent, and highly selective Hippo pathway inhibitor. This early look at the IK-930 dose escalation data strongly supports the differentiated approach to targeting the Hippo pathway. With no approved standard of care, there is substantial need for innovative treatments that can provide clinical benefit and symptom relief and slow or limit the progression of disease.

ven patatients with EHE have been treated with IK-930 in the dose escalation portion of the trial; 7 out of 7 EHE patients reached stable disease as a best response so far as measured by RECIST; 3 out of the 7 patients experienced tumor shrinkage in multiple target and non-target lesions; 4 out of 7 highly symptomatic EHE patients enrolled across multiple dose levels reported symptomatic improvement and subject improvement of quality of life such as improved energy, weight gain, and pain control; 3 out of the 7 patient continue on treatment with time on treatment ranging from 18 to 26 weeks and ongoing; As a result of these initial tolerability and antitumor activity findings, enrollment in the dose escalation phase continues to progress in targeted populations including mesothelioma and meningioma, in addition to EHE; Based on preclinical data indicating IK-930 synergy with EGFR inhibitors to combat therapeutic resistance, a combination cohort for IK-930 andosimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC) is planned to initiate in 2024; An additional data update from the IK-930 clinical program is planned for the second half of 2024.